160 related articles for article (PubMed ID: 17263128)
1. Targeting metastatic prostate cancer: the search for innovative systemic therapies.
Berthold DR; Moore MJ
Oncology (Williston Park); 2006 Dec; 20(14):1787-91; discussion 1791-6. PubMed ID: 17263128
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
5. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
Masson S; Bahl A
BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
[TBL] [Abstract][Full Text] [Related]
6. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
7. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of advanced prostate cancer.
Ismail M; Gomella LG
Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
[TBL] [Abstract][Full Text] [Related]
9. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
10. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Rezvani H; Haghighi S; Ghadyani M; Attarian H
Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
13. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
14. Novel chemotherapies in development for management of castration-resistant prostate cancer.
Tewari AK; George DJ
Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
[TBL] [Abstract][Full Text] [Related]
15. [New perspectives in the drug therapy of hormone-resistant prostate cancer].
Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM
Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118
[No Abstract] [Full Text] [Related]
16. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
Droz JP; Chaladaj A
BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in management of advanced prostate cancer.
Kantoff P
Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
[TBL] [Abstract][Full Text] [Related]
18. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
19. Role of targeted therapy in the treatment of advanced prostate cancer.
Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]